Zobrazeno 1 - 10 of 58 pro vyhledávání: '"Paul B. Iannini"'
1
The safety profile of moxifloxacin and other fluoroquinolones in special patient populations
Autor: Paul B. Iannini
Publikováno v: Current Medical Research and Opinion. 23:1403-1413
Fluoroquinolones, including ciprofloxacin, levofloxacin, gemifloxacin, and moxifloxacin, represent a major advance in the development of antimicrobial agents. They offer significant activity against Gram-negative pathogens, while more advanced genera
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05447ff00340a2c7a75347b8610290ea
https://doi.org/10.1185/030079907x188099
Zobrazit plný text záznamu
2
Adverse Cutaneous Reactions and Drugs: A Focus on Antimicrobials
Autor: G. Patou, J. Felmingham, Paul B. Iannini, G.S. Tillotson, Lionel A. Mandell
Publikováno v: Journal of Chemotherapy. 18:127-139
Rashes are a common adverse event observed during antimicrobial therapy. Many rashes are mild to moderate in intensity, however some reactions can be the prelude to much more severe outcomes such as Stevens-Johnson Syndrome (SJS) or Toxic Epidermal N
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db5f7d919d825980de31cfadfd1a1783
https://doi.org/10.1179/joc.2006.18.2.127
Zobrazit plný text záznamu
3
Cutaneous Adverse Events and Gemifloxacin: Observations from the Clinical Trial Program
Autor: N. Shear, Paul B. Iannini, G. Patou, Lionel A. Mandell
Publikováno v: Journal of Chemotherapy. 18:3-11
Cutaneous adverse events are seen with many antimicrobials. A signal was observed with gemifloxacin in the original clinical research program, however subsequent studies and analysis demonstrated a mild-moderate self-limited macular-papular rash seen
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4ed3fa939b29e8c6362f728e2c39e0a
https://doi.org/10.1179/joc.2006.18.1.3
Zobrazit plný text záznamu
4
Moxifloxacin (Avelox®): a novel fluoroquinolone with a broad spectrum of activity
Autor: Juan-Pablo Caeiro, Paul B Iannini
Publikováno v: Expert Review of Anti-infective Therapy. 1:363-370
Moxifloxacin (Avelox) is a recently-developed fluoroquinolone that has a broad spectrum of antimicrobial activity, including typical respiratory pathogens, atypical and intracellular respiratory pathogens, Gram-negative pathogens and many anaerobes.
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eefe10e06ada38c9d3dc0400dd4b941b
https://doi.org/10.1586/14787210.1.3.363
Zobrazit plný text záznamu
5
Emergence of fluoroquinolone resistance among Bacteroides species
Autor: Lizzie J. Harrell, Sherwood L. Gorbach, Jack Rihs, Richard A. Venezia, Ellie J. C. Goldstein, Stephen G. Jenkins, David W. Hecht, Nilda V. Jacobus, Paul B. Iannini, David R. Snydman, Laura A. McDermott, Carl L. Pierson, Yoav Golan, Sydney M. Finegold
Publikováno v: Journal of Antimicrobial Chemotherapy. 52:208-213
Background: Several newer generation fluoroquinolones have demonstrated good in vitro activity against Bacteroides species; particularly when first introduced. However, resistance of Bacteroides to quinolones appears to be increasing. Materials and m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e909f4813a8049cfeb6802e111a89968
https://doi.org/10.1093/jac/dkg320
Zobrazit plný text záznamu
6
Impact of Initial Antibiotic Choice on Clinical Outcomes in Community-Acquired Pneumonia
Autor: Richard B. Brown, Paul B. Iannini, Peter A. Gross, Mark Kunkel
Publikováno v: Chest. 123:1503-1511
Background: Much controversy exists regarding the initial choice of antibiotics and selected outcomes for patients with community-acquired pneumonia (CAP). Methods: The investigators analyzed a hospital claims-made database to assess the impact of in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d95661e6adc51cf67c3ce57c8302770c
https://doi.org/10.1378/chest.123.5.1503
Zobrazit plný text záznamu
7
Multicenter Study of In Vitro Susceptibility of the Bacteroides fragilis Group, 1995 to 1996, with Comparison of Resistance Trends from 1990 to 1996
Autor: Sherwood L. Gorbach, J. Rihs, Laura A. McDermott, Stacey Supran, Paul B. Iannini, Carl L. Pierson, G J Cuchural, S. Jenkins, Nilda V. Jacobus, David W. Hecht, David R. Snydman, Sydney M. Finegold, Lizzie J. Harrell
Publikováno v: Europe PubMed Central
Scopus-Elsevier
Antimicrobial resistance, including plasmid-mediated resistance, among the species of the Bacteroides fragilis group is well documented. An analysis of the in vitro susceptibility of B. fragilis group species referred between 1995 and 1996 as well as
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed0f2ee7a92998a080509ce73c8c57b9
https://doi.org/10.1128/aac.43.10.2417
Zobrazit plný text záznamu
9
Gatifloxacin-Associated Corrected QT Interval Prolongation, Torsades de Pointes, and Ventricular Fibrillation in Patients with Known Risk Factors
Autor: Timothy D. Carnes, Paul B. Iannini, Joseph S. Bertino, Robert C. Owens
Publikováno v: Clinical Infectious Diseases. 34:861-863
Drugs not commonly considered to be cardioactive agents have been reported to cause prolongation of the corrected QT interval with resultant torsades de pointes or ventricular fibrillation. We report 4 cases of gatifloxacin-associated cardiac toxicit
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::148617af7a5c4a73e2125c496837e76e
https://doi.org/10.1086/339075
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje